We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oncology Drug Reference Sheet: Decitabine and Cedazuridine.
- Authors
LeFebvre, Kristine B.
- Abstract
The article informs about oncology drug reference sheet, and reports the U.S. Food and Drug Administration approved decitabine and cedazuridine tablets for the treatment of adults with myelodysplastic syndromes. Topics include oral formulation of the antimetabolite decitabine combined with an inhibitor of the enzyme that degrades decitabine in the gastrointestinal tract; and dose modifications or delays are recommended for hematologic toxicity, increased serum creatinine, and infection.
- Subjects
MYELODYSPLASTIC syndromes; DRUG approval; ANTINEOPLASTIC agents; DECITABINE; PHARMACY information services; DRUG side effects; ENZYME inhibitors
- Publication
ONS Voice, 2021, Vol 36, Issue 3, p34
- ISSN
2475-6938
- Publication type
Article